论文部分内容阅读
血管紧张素转换酶抑制剂巯甲丙脯氨酸临床用于治疗严重心力衰竭的疗效已经确认,但过去该药仅限于口服。本文作者首次采用静脉给予巯甲丙脯氨酸对26例严重心力衰竭病人进行了研究,其中14例接受一次量25mg,12例接受递增量(范围0.3125——45mg)。在给予25mg 量后,体血管阻力和体动脉血压迅速下降,5分钟作用达高峰,此时心排量增加20%,平均右房压和肺动脉舒张末期压降压较慢,60分钟时达高峰。在注入15分钟后,血浆游离巯甲
The clinical efficacy of angiotensin-converting enzyme inhibitor captopril in the treatment of severe heart failure has been confirmed, but in the past it had been limited to oral administration. The authors first conducted a study of 26 patients with severe heart failure by intravenous administration of captopril, of which 14 received a single dose of 25 mg and 12 received incremental doses (range, 0.3125 - 45 mg). After administration of 25 mg of body weight, systemic vascular resistance and body arterial pressure decreased rapidly and peaked at 5 minutes. At this time, cardiac output increased by 20%. Average right atrial pressure and pulmonary end-diastolic pressure drop were slower and reached peak at 60 minutes . After 15 minutes of infusion, plasma is free of capsaicin